Laurent Renia

Prof. Laurent Renia

Lee Kong Chian School of Medicine, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2020 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MTMatthew Zirui Tay
Matthew Zirui Tay
CPChek Meng Poh
Chek Meng Poh
LRLaurent Renia
Laurent Renia
PMPaul A. MacAry
Paul A. MacAry
LNLisa F.P. Ng
Lisa F.P. Ng

8 June 2015 in Nature Immunology
Verified
Journal Article
Closed access
ASAndreas Schlitzer
Andreas Schlitzer
VSV Sivakamasundari
V Sivakamasundari
JCJinmiao Chen
Jinmiao Chen
HSHermi Rizal Bin Sumatoh
Hermi Rizal Bin Sumatoh
JSJaring Schreuder
Jaring Schreuder
FGFlorent Ginhoux
Florent Ginhoux

9 June 2017 in Science
Verified
Journal Article
Closed access
PDF file
PSPeter See
Peter See
CDCharles-Antoine Dutertre
Charles-Antoine Dutertre
JCJinmiao Chen
Jinmiao Chen
PGPatrick Günther
Patrick Günther
NMNaomi McGovern
Naomi McGovern
FGFlorent Ginhoux
Florent Ginhoux
Tracing development of the dendritic cell lineage: Dendritic cells (DCs) are important components of the immune system that form from the bone marrow into two major cell lineages: plasmacytoid DCs and conventional DCs. Seeet al.applied single-cell RNA sequencing and cytometry by time-of-flight to characterize the developmental pathways of these cells. They identified blood DC precursors that shared surface markers with plasmacytoid DCs but that were functionally distinct. This unsuspected level of complexity in pre-DC populations reveals additional cell types and refines understanding of known cell types.Science, this issue p.eaag3009

19 October 2020 in Nature Reviews Nephrology
Verified
Journal Article
Open access
PDF file
LPLuca Perico
Luca Perico
ABAriela Benigni
Ariela Benigni
FCFederica Casiraghi
Federica Casiraghi
LNLisa F.P. Ng
Lisa F.P. Ng
LRLaurent Renia
Laurent Renia
Giuseppe RemuzziGiuseppe Remuzzi
Giuseppe Remuzzi
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a pathogenic condition that has been termed coronavirus disease 2019 (COVID-19) and has reached pandemic proportions. As of 17 September 2020, more than 30 million confirmed SARS-CoV-2 infections have been reported in 204 different countries, claiming more than 1 million lives worldwide. Accumulating evidence suggests that SARS-CoV-2 infection can lead to a variety of clinical conditions, ranging from asymptomatic to life-threatening cases. In the early stages of the disease, most patients experience mild clinical symptoms, including a high fever and dry cough. However, 20% of patients rapidly progress to severe illness characterized by atypical interstitial bilateral pneumonia, acute respiratory distress syndrome and multiorgan dysfunction. Almost 10% of these critically ill patients subsequently die. Insights into the pathogenic mechanisms underlying SARS-CoV-2 infection and COVID-19 progression are emerging and highlight the critical role of the immunological hyper-response — characterized by widespread endothelial damage, complement-induced blood clotting and systemic microangiopathy — in disease exacerbation. These insights may aid the identification of new or existing therapeutic interventions to limit the progression of early disease and treat severe cases.

1 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPChek Meng Poh
Chek Meng Poh
GCGuillaume Carissimo
Guillaume Carissimo
BWBei Wang
Bei Wang
SASiti Naqiah Amrun
Siti Naqiah Amrun
CLCheryl Yi-Pin Lee
Cheryl Yi-Pin Lee
LNLisa F.P. Ng
Lisa F.P. Ng
Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.

14 October 2011 in Scientific Reports
Verified
Journal Article
Open access
Benoit MalleretBenoit Malleret
Benoit Malleret
CCCarla Claser
Carla Claser
AOAlice Soh Meoy Ong
Alice Soh Meoy Ong
RSRossarin Suwanarusk
Rossarin Suwanarusk
KSKanlaya Sriprawat
Kanlaya Sriprawat
LRLaurent Renia
Laurent Renia
Microscopic examination of Giemsa-stained thin blood smears remains the gold standard method used to quantify and stage malaria parasites. However, this technique is tedious, and requires trained microscopists. We have developed a fast and simple flow cytometry method to quantify and stage, various malaria parasites in red blood cells in whole blood or in vitro cultured Plasmodium falciparum. The parasites were stained with dihydroethidium and Hoechst 33342 or SYBR Green I and leukocytes were identified with an antibody against CD45. Depending on the DNA stains used, samples were analyzed using different models of flow cytometers. This protocol, which does not require any washing steps, allows infected red blood cells to be distinguished from leukocytes, as well as allowing non-infected reticulocytes and normocytes to be identified. It also allows assessing the proportion of parasites at different developmental stages. Lastly, we demonstrate how this technique can be applied to antimalarial drug testing.